Neoplasia

Papers
(The H4-Index of Neoplasia is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Epitranscriptomic mechanisms of androgen signalling and prostate cancer1628
Corrigendum to “Tumorigenicity of IL-1α- and IL-1β-Deficient Fibrosarcoma Cells” [Neoplasia, Volume 10, Issue 6, June 2008, Pages 549–562]114
DHX34 deficiency triggers tumor-intrinsic immunity via a dsRNA-mediated type I interferon pathway activation in HCC96
Corrigendum to “Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells” [Neoplasia 17 (2014) 85]56
ARID1A loss sensitizes colorectal cancer cells to floxuridine55
Visualizing mast cell migration to tumor sites using sodium iodide symporter of nuclear medicine reporter gene53
Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma51
High metastatic tumor-derived CXCL16 mediates liver colonization metastasis by inducing Kupffer cell polarization via the PI3K/AKT/FOXO3a pathway48
5-Aza-2′-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD43
Sialylated IgG-activated integrin β4-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis42
The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells41
L-methionine promotes CD8+ T cells killing hepatocellular carcinoma by inhibiting NR1I2/PCSK9 signaling41
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma41
Retraction notice to “Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors” [Neoplasia 18 (2016) 347- 355/201]40
Mutational signatures and their association with survival and gene expression in urological carcinomas39
From adenoma to CRC stages: the oral-gut microbiome axis as a source of potential microbial and metabolic biomarkers of malignancy39
Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer38
Time-restricted feeding affects the fecal microbiome metabolome and its diurnal oscillations in lung cancer mice36
Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy36
Tumor-Infiltrating Immune Cells in Colorectal Cancer35
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine34
Myxoid glioneuronal tumor: Histopathologic, neuroradiologic, and molecular features in a single center series33
RUNX2 enhances bladder cancer progression by promoting glutamine metabolism31
Advanced progress of spatial metabolomics in head and neck cancer research30
Rezatapopt: A promising small-molecule “refolder” specific for TP53Y220C mutant tumors30
Leptomeningeal dissemination in pediatric brain tumors30
Innate immunity: Looking beyond T-cells in radiation and immunotherapy combinations28
0.41642904281616